What Is GHK-Cu? GHK, Copper & Evidence Status

GHK nomenclature

GHK is the abbreviation for a tripeptide: glycyl-L-histidyl-L-lysine. In one-letter notation it is written GHK; in three-letter notation, Gly-His-Lys. That three-amino-acid sequence is the chemical identity tissue-remodeling reviews use when they discuss the human peptide.¹

This page answers “what is it.” It does not score wrinkles, summarize wounds, or interpret compounding. Those questions have their own pages in the GHK-Cu research hub.

Tripeptide identity

Three amino acids define a tripeptide. GHK is not a drug because it exists in plasma or tissues, and it is not a treatment because it was isolated in a laboratory. It is a small molecule with a specific sequence.¹

Reviews describe GHK as a human tripeptide associated, in the literature, with remodeling processes. That historical association explains research interest. It does not make GHK an approved product or a use instruction.^1,2

When a certificate of analysis or a catalog reproduces Gly-His-Lys, it is speaking about analytical identity. That match does not carry a clinical skin outcome with it.

Copper binding and complex formation

GHK-Cu is the complex or chelate formed when GHK binds copper(II). Copper is not an ornament on the name: it changes the chemical identity of the object under study. Much of the matrix and skin literature refers to that complex, not to the free tripeptide in every sentence.²

At a high level, GHK can coordinate copper. That coordination chemistry is the bridge between the tripeptide and the complex. It is not, by itself, proof of a visible effect in people.

GHK versus GHK-Cu

GHK names the tripeptide. GHK-Cu names the copper complex. Treating them as perfect synonyms hides that difference. A finding described for the complex cannot be copied, without more, onto every mention of GHK, and the reverse is also true.

In marketing, “GHK,” “GHK-Cu,” and “copper peptide” are mixed as if they were the same label. In this cluster they stay separate. The mechanistic detail is in proposed mechanisms and extracellular-matrix biology.

What “copper peptide” means

“Copper peptide” is a broad descriptive category. It can cover more than one peptide–copper complex. GHK-Cu is one specific complex. In cosmetic nomenclature it sometimes appears as copper tripeptide-1. That catalog label does not make every serum that uses the same marketing phrase equivalent.⁶

A separate thin page on “what are copper peptides” is not needed. The informational intent belongs here and on the cluster hub. A thin duplicate would cannibalize this definition.

A commercial serum is not, by name, a trial formulation. Formulation, vehicle, and route matter. That limitation returns in the skin and wound evidence.

Why it has attracted research interest

The interest does not come from a mature clinical program. It comes from a small human molecule, from copper-coordination chemistry, and from decades of work on fibroblasts, extracellular matrix, remodeling, and wound models.^1,2,7

Widespread cosmetic use sits on top of that. Widespread use is not evidence. A recent topical review concludes that published clinical information remains insufficient despite that use.⁶

Four layers need to stay separate: biological plausibility, preclinical evidence, human clinical evidence, and marketing claims. This page names the layers. It does not flatten them.

Human versus preclinical evidence

The preclinical and biochemical literature is substantial. Rigorous human clinical evidence is much smaller. A 2026 systematic review searched PubMed, Embase, and Cochrane CENTRAL through March 2026 and included 20 studies: 18 preclinical and 2 randomized trials.³

That is not summarized as a demonstrated clinical wrinkle effect. The inventory is in human clinical studies and the skin detail is in what the clinical evidence actually shows for skin.

A Phase 2 topical trial, NCT07437586, is listed as recruiting as of 1 September 2026 and has no posted results. An active registry record is not efficacy.⁵

Regulatory status

GHK-Cu is not an FDA-approved drug. The 22 April 2026 update describes 503A category changes because nominations were withdrawn, and an intention to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. That is not approval and not a final listing decision.⁸

The immunogenicity concern FDA has described refers to compounded drugs for injectable routes, not to topical skin-trial evidence. The detail is in FDA and compounding status.⁹

What it is not proven to do

• GHK-Cu is not established as a “powerful anti-aging peptide” or a “skin-regeneration peptide.” Those phrases are marketing language, not an established scientific classification.^6,3
• The 2006 trial’s objective outcomes do not establish that it reduces wrinkles or improves overall skin quality with statistical significance.⁴
• A recruiting trial does not demonstrate that it heals wounds.⁵
• This page is not a cosmetic recommendation, does not specify a formulation, and does not describe an application technique.

A certificate of analysis documents lot identity and purity. See the GHK-Cu certificate archive. That does not demonstrate a clinical effect.